Relief Therapeutics Holding AG (RLFTF)

[tcm55]

Dr JJ and NRXP cant steal RLF-100 for themselves, RLF has the patent.

From NRX/RLF PR about Trial enrollment complete 12-30

Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.